Modality
Nanobody
MOA
CGRPant
Target
EZH2
Pathway
PI3K/AKT
HCCSMAUrothelial Ca
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
Dec 2022
→ Nov 2030
Phase 1Current
NCT05744971
44 pts·HCC
2022-12→2030-11·Terminated
NCT05319394
543 pts·HCC
2024-03→2027-02·Terminated
587 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-0810mo awayPh2 Data· HCC
2030-11-284.7y awayPh2 Data· HCC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2027-02-08 · 10mo away
HCC
Ph2 Data
2030-11-28 · 4.7y away
HCC
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05744971 | Phase 1/2 | HCC | Terminated | 44 | DAS28 |
| NCT05319394 | Phase 1/2 | HCC | Terminated | 543 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa |